NCT04328272: Covid

Effectiveness of Hydroxychloroquine in Covid-19 Patients

Status unknown Phase 3 Last updated 2 April 2020

What this trial tests

Phase 3 trial testing Hydroxychloroquine 200 Mg Oral Tablet in COVID19 in 75 participants. Status unknown.

Timeline

28 March 2020

Primary endpoint
28 May 2020

28 June 2020

Quick facts

Lead sponsor	Prof. Dr. Umar Farooq
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	75
Start date	28 March 2020
Primary completion	28 May 2020
Estimated completion	28 June 2020
Sites	1 location across Pakistan

Drugs / interventions tested

• Hydroxychloroquine 200 Mg Oral Tablet
• Azithromycin 500Mg Oral Tablet — full drug profile →
• Glucose tablets

Conditions studied

• COVID19 — all drugs for COVID19 →

Sponsor

Prof. Dr. Umar Farooq

Who can join

Adults 18 to 50, any sex, with COVID19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To find the effectiveness of hydroxychloroquine alone and adjuvant with azithromycin in mild to severe Covide-19 pneumonia patients admitted to Coronavirus cell/ward of Ayub Teaching hospital, Abbottabad Pakistan. A single centered, single-blind randomized control trial study.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. COVID-19: Characteristics and Therapeutics.
   Chilamakuri R, Agarwal S. · · 2021 · cited 192× · PMID 33494237 · DOI 10.3390/cells10020206
2. An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
   Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
3. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy.
   Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2020 · cited 105× · PMID 32717568 · DOI 10.1016/j.drup.2020.100719
4. Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review.
   Hashem AM, Alghamdi BS, Algaissi AA, Alshehri FS, et al · · 2020 · cited 85× · PMID 32387694 · DOI 10.1016/j.tmaid.2020.101735
5. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology.
   Pani A, Lauriola M, Romandini A, Scaglione F. · · 2020 · cited 73× · PMID 32534189 · DOI 10.1016/j.ijantimicag.2020.106053
6. Antibiotics for the treatment of COVID-19.
   Popp M, Stegemann M, Riemer M, Metzendorf MI, et al · · 2021 · cited 60× · PMID 34679203 · DOI 10.1002/14651858.cd015025
7. The current understanding and potential therapeutic options to combat COVID-19.
   Pooladanda V, Thatikonda S, Godugu C. · · 2020 · cited 56× · PMID 32437797 · DOI 10.1016/j.lfs.2020.117765
8. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19.
   Homolak J, Kodvanj I. · · 2020 · cited 54× · PMID 32522674 · DOI 10.1016/j.ijantimicag.2020.106044